• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Chinese guidelines for diagnosis and treatment of myelodysplastic syndromes (2019)].

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2019 Feb 14;40(2):89-97. doi: 10.3760/cma.j.issn.0253-2727.2019.02.001.

DOI:10.3760/cma.j.issn.0253-2727.2019.02.001
PMID:30831622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342655/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23ed/7342655/e99d809cfe8d/cjh-40-02-089-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23ed/7342655/e99d809cfe8d/cjh-40-02-089-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23ed/7342655/e99d809cfe8d/cjh-40-02-089-g001.jpg

相似文献

1
[Chinese guidelines for diagnosis and treatment of myelodysplastic syndromes (2019)].《中国骨髓增生异常综合征诊断与治疗指南（2019年版）》
Zhonghua Xue Ye Xue Za Zhi. 2019 Feb 14;40(2):89-97. doi: 10.3760/cma.j.issn.0253-2727.2019.02.001.
2
Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases.骨髓增生异常综合征、慢性骨髓增殖性疾病及骨髓增生异常/骨髓增殖性疾病。
Semin Diagn Pathol. 2003 Aug;20(3):154-79. doi: 10.1016/s0740-2570(03)00025-x.
3
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.流式细胞术在骨髓增生异常综合征诊断模型中进行红系谱系分析的应用
Haematologica. 2017 Feb;102(2):320-326. doi: 10.3324/haematol.2016.147843. Epub 2016 Sep 22.
4
Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.一项多中心研究强调，在骨髓增生异常综合征和骨髓增生异常/骨髓增殖性肿瘤中，将CD5、CD7和CD56表达评估添加到流式细胞术绪方评分中的意义。
Haematologica. 2015 Apr;100(4):472-8. doi: 10.3324/haematol.2014.112755. Epub 2015 Jan 30.
5
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.骨髓增生异常综合征中的铁过载：来自加拿大骨髓增生异常综合征联盟的循证指南
Leuk Res. 2018 Nov;74:21-41. doi: 10.1016/j.leukres.2018.09.005. Epub 2018 Sep 19.
6
[Chinese experts consensus statement on diagnosis and treatment of myelodysplastic syndromes in children, 2015].《中国儿童骨髓增生异常综合征诊断与治疗专家共识（2015年版）》
Zhonghua Er Ke Za Zhi. 2015 Nov;53(11):804-9.
7
[Management of myelodysplastic syndromes in 2019: An update].《2019年骨髓增生异常综合征的管理：最新进展》
Rev Med Interne. 2019 Sep;40(9):581-589. doi: 10.1016/j.revmed.2019.04.001. Epub 2019 May 1.
8
CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.来自急性髓系白血病、骨髓增生异常综合征和正常骨髓的CD34+细胞表现出不同的凋亡和耐药相关表型。
Clin Cancer Res. 2004 Nov 15;10(22):7599-606. doi: 10.1158/1078-0432.CCR-04-0598.
9
[Serum Erythropoietin as Prognostic Marker in Myelodysplastic Syndromes].[血清促红细胞生成素作为骨髓增生异常综合征的预后标志物]
Acta Med Port. 2015 Nov-Dec;28(6):720-5. Epub 2015 Dec 31.
10
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.芦可替尼治疗低危骨髓增生异常综合征相关贫血患者（PACE-MDS）：一项多中心、开放标签、2 期剂量发现研究和长期扩展研究。
Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1.

引用本文的文献

1
[Analysis of the association between pre- and post-treatment genetic mutation status and treatment efficacy and survival in patients with newly diagnosed myelodysplastic syndromes with excess blasts receiving hypomethylating agent therapy].[新诊断的伴过多原始细胞的骨髓增生异常综合征患者接受去甲基化药物治疗前后基因突变状态与治疗疗效及生存的相关性分析]
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):417-424. doi: 10.3760/cma.j.cn121090-20241210-00553.
2
[Dynamic changes in genetic mutations in myelodysplastic neoplasms with progressive disease and leukemic transformation].[骨髓增生异常肿瘤伴疾病进展和白血病转化过程中基因突变的动态变化]
Zhonghua Xue Ye Xue Za Zhi. 2025 Mar 14;46(3):252-260. doi: 10.3760/cma.j.cn121090-20240708-00254.
3

本文引用的文献

1
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.骨髓增生异常综合征（MDS）及潜在的MDS前期病症的拟议最低诊断标准。
Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.
2
Guidelines for the diagnosis and management of adult myelodysplastic syndromes.成人骨髓增生异常综合征的诊断与管理指南
Br J Haematol. 2014 Feb;164(4):503-25. doi: 10.1111/bjh.12694. Epub 2013 Dec 23.
3
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.
Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging study.来特司特（luspatercept）治疗亚洲需要红细胞输注的伴有环形铁粒幼细胞的骨髓增生异常综合征相关贫血的安全性和有效性：一项II期桥接研究
Ther Adv Hematol. 2025 Feb 20;16:20406207251321715. doi: 10.1177/20406207251321715. eCollection 2025.
4
[Pure white cell aplasia combined with thymoma and lung cancer: a case report and literature review].[纯红细胞再生障碍性贫血合并胸腺瘤和肺癌：1例报告及文献复习]
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):789-793. doi: 10.3760/cma.j.cn121090-20240113-00018.
5
[Long-term hypomethylating agents in patients with myelodysplastic syndromes: a multi-center retrospective study].[长期低甲基化药物治疗骨髓增生异常综合征患者：一项多中心回顾性研究]
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):738-747. doi: 10.3760/cma.j.cn121090-20240405-00124.
6
Effects of exosomes and inflammatory response on tumor: a bibliometrics study and visualization analysis via CiteSpace and VOSviewer.外泌体与炎症反应对肿瘤的影响：基于 CiteSpace 和 VOSviewer 的文献计量学研究与可视化分析。
J Cancer Res Clin Oncol. 2024 Aug 30;150(8):405. doi: 10.1007/s00432-024-05915-y.
7
[Analysis and summary of clinical characteristics of 289 patients with paroxysmal nocturnal hemoglobinuria in Zhejiang Province].浙江省289例阵发性睡眠性血红蛋白尿症患者临床特征分析与总结
Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):549-555. doi: 10.3760/cma.j.cn121090-20240127-00041.
8
[Analysis of the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome with blastomycosis and survival comparison of different subtypes after the WHO 2022 reclassification].[骨髓增生异常综合征合并母细胞增多症患者异基因造血干细胞移植的疗效及预后因素分析以及2022年世界卫生组织重新分类后不同亚型的生存比较]
Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):445-452. doi: 10.3760/cma.j.cn121090-20231109-00258.
9
[Efficacy and safety analysis of hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in low-risk myelodysplastic syndromes patients].低危骨髓增生异常综合征患者贫血应用缺氧诱导因子脯氨酰羟化酶抑制剂的疗效与安全性分析
Zhonghua Xue Ye Xue Za Zhi. 2024 Mar 14;45(3):290-293. doi: 10.3760/cma.j.cn121090-20230825-00089.
10
[Efficacy and safety of venetoclax combined with hypomethylating agents in the treatment of 83 patients with higher-risk myelodysplastic syndromes].维奈托克联合去甲基化药物治疗83例高危骨髓增生异常综合征患者的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2024 Mar 14;45(3):277-283. doi: 10.3760/cma.j.cn121090-20231207-00296.
成人原发性骨髓增生异常综合征的诊断和治疗：欧洲白血病网络的建议。
Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26.
4
Revised international prognostic scoring system for myelodysplastic syndromes.修订版国际预后积分系统用于骨髓增生异常综合征。
Blood. 2012 Sep 20;120(12):2454-65. doi: 10.1182/blood-2012-03-420489. Epub 2012 Jun 27.
5
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).贫血程度对骨髓增生异常综合征患者结局的影响及其在基于世界卫生组织分类的预后评分系统（WPSS）中的整合。
Haematologica. 2011 Oct;96(10):1433-40. doi: 10.3324/haematol.2011.044602. Epub 2011 Jun 9.
6
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.国际工作组（IWG）骨髓增生异常综合征反应标准的临床应用及修订建议
Blood. 2006 Jul 15;108(2):419-25. doi: 10.1182/blood-2005-10-4149. Epub 2006 Apr 11.
7
International scoring system for evaluating prognosis in myelodysplastic syndromes.评估骨髓增生异常综合征预后的国际评分系统。
Blood. 1997 Mar 15;89(6):2079-88.
8
Proposals for the classification of the myelodysplastic syndromes.骨髓增生异常综合征的分类建议。
Br J Haematol. 1982 Jun;51(2):189-99.